ICON PLC Financial Update
ICON PLC, a leading contract clinical research service provider in the global pharmaceutical industry, is set to release its quarterly financial results on July 23, 2025. The company, listed on the Nasdaq, is expected to report a significant increase in its quarterly earnings per share (EPS) compared to the same period last year. Analysts anticipate an EPS of $3.19, up from $1.76 in the previous year. However, revenue is projected to decline by 6.53% to $1.98 billion, down from $2.12 billion in the prior year’s quarter.
For the full fiscal year, analysts predict a more optimistic outlook, with an expected EPS of $13.24, compared to $9.53 in the previous year. Revenue forecasts suggest a slight decrease to $7.96 billion from $8.28 billion in the prior year.
Annual General Meeting Outcomes
On July 22, 2025, ICON PLC held its Annual General Meeting (AGM), where all resolutions were passed by shareholders. Key resolutions included the re-election of several board members, including Mr. Ciaran Murray, Dr. Steve Cutler, Mr. Rónán Murphy, Dr. John Climax, Ms. Julie O’Neill, Mr. Eugene McCague, Dr. Linda Grais, and Ms. Anne Whitaker. The meeting also approved the review of the company’s affairs, the accounts and reports, and ratified the appointment of EY as the audit firm.
Second Quarter 2025 Financial Highlights
ICON PLC reported strong performance in the second quarter of 2025. Gross business wins reached $2.966 billion, marking a 10.6% increase from the first quarter of 2025. Net business wins were $2.057 billion, with a net book to bill ratio of 1.02. Revenue for the quarter was $2,017.4 million, a 0.8% increase from the first quarter.
The company achieved a net income of $183.0 million, or $2.30 per diluted share, representing a 30.7% increase from the second quarter of 2024. Adjusted EBITDA for the quarter was $396.0 million, or 19.6% of revenue, up 1.4% from the first quarter. Adjusted net income was $259.5 million, or $3.26 per diluted share.
ICON PLC’s net debt stood at $3.0 billion as of June 30, 2025, with a net debt to adjusted EBITDA ratio of 1.9x. The company repurchased $250.0 million worth of stock in the second quarter at an average price of $146 per share. Additionally, the board authorized an expansion of the share repurchase program by $500 million, bringing the total authorized share repurchases to $1 billion.
The company has also updated its full-year 2025 financial guidance, increasing the revenue range to $7,850 million to $8,150 million, up $50 million at the midpoint from the previous guidance. Adjusted diluted earnings per share guidance for the full year has been updated to a range of $13.00 to $13.50.